Canadian scientists, others around the world compete for the COVID-19 vaccine

No vaccine for COVID-19 is required for one year or more, Canadian researchers are one of thousands of researchers worldwide competing to find a way to vaccinate people the new organism.

Back in January, China announced the genetics of the virus, launching guns for millions of studies around the world, with human trials around it.

The world awaits with regular breathing, the World Health Organization last week asked for a change to health strategies that allow us to “stay healthy.” with the virus ”until vaccinated.

CTV News senior infectious disease expert Dr Abdu Sharkawy said there was no question that “a study in Canada was looking for a vaccine for COVID-19.

“Although we are very happy and we are happy to see that there has been a great deal of cooperation between people in Canada and around the world, I can’t understand the fact that vaccines are not our way solve this problem, ”Sharkawy said.

“The vaccine is what we want to see in the future. This will take several months of development when we address the purification of drugs from vaccines as the latest standards for animal testing, looking at experimental and healthy populations. following safety measures beyond that. ”

Vaccines work by introducing certain strains of the virus to the human immune system, most of which are injected by injection, to allow the body to produce antibodies against the virus. .

Clinics, one of the most important precursors to regulatory approval, are often made in three sections, according to the Guardian.

First, join a few dozen health workers, evaluate the vaccine for safety and monitor for possible side effects. Second, join hundreds of people, most in a part of the world affected by the disease, to see how effective the vaccine is and the third is not the same in many thousands of people.


In Canada, vaccination programs are already under way at least for college, according to Canadian Press.

Researchers at the University of Saskatchewan are trying to find out which species and species are more likely to become infected to better understand which animals are most at risk.

The team will also use animals to make vaccines to prevent the spread of the virus and determine if animals can be tested for the safety of the vaccine.

At Laval University in Quebec City, existing researchers against the Zika virus and MERS are aiming to develop the COVID-19 vaccine by reverse-regulating the genetics of the virus. newl coronavirus.

Laval is also responsible for the project hoping to use microscopic nanoparticles to improve the strength of the immune system and the speed of that response for any new vaccine.

A University of Alberta researcher and his biotech research company are working on a DNA-vaccine for COVID-19.

And University of British Columbia researchers are reviewing the efficacy of previous vaccines against the new coronavirus.

“We’re looking at a couple of months at the very least, we can’t afford to look forward,” Sharkawy said.

“Now, we need to make a concerted effort to curb the spread of the virus now in our homes, in our community. So hand washing, physically away, make sure we take care of all sections of the neighborhood. That’s more important. Please do not look at vaccines as a way of doing this. “


The Guardian reports that about 35 companies and educational institutions are working to develop vaccines, at least four of which have been tested in animals.

The first of these, created by Boston-based biotech firm Moderna, will be accessible to human trials.

Annelies Wilder-Smith, associate professor of infectious diseases at the London School of Obstetrics and Gynecology, told the newspaper: “Like people vaccinated. vaccines.

Johnson & Johnson said on Monday that he has selected a new vaccine leader who will transition to a human trial in September and can be prepared for emergency use by the agency. next year.

The medical company has signed an agreement with the United States Life Science and Technology Research Institute to invest $ 1 billion in development lighter

The journal Science, the peer-reviewed journal of the American Academy of Sciences, stated that the development of the COVID-19 vaccine could be used internationally on a single-dose scale. the reason for the development of the rocket.

Reports suggest that 44 vaccines in early development and adequate production of vaccines will eventually require international collaboration.

The G20 nations on Thursday announced a US $ 5-trillion budget to boost global trade and pledged to “work together to increase research and development funding.” for vaccinations and medicines. ”

Oslo-in a non-profit initiative for the Integrated Vaccine Development Program, which is funded to collaborate and collaborate on the development of the COVID-19 vaccine , reached US $ 2 billion.

Meanwhile, the United States is funding a number of companies through its Department of Health and Human Services and the National Institutes of Health, according to AFP.

French pharmacist Sanofi has partnered with the US government to develop vaccines, while teams at the University of Texas also have candidates ready.

– With information from Canadian Publications, Partners and AFP


Source link